

Best Practices in Multiple Myeloma Care: Opportunities to Improve Outcomes in Community Settings

References

Abdallah N, Kumar SK. Daratumumab in untreated newly diagnosed multiple myeloma. *Ther Adv Hematol*. 2019;10:2040620719894871. doi: 10.1177/2040620719894871.

Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. *Clin Cancer Res*. 2013;19(5):985-94. doi: 10.1158/1078-0432.CCR-12-2922. Epub 2012 Dec 5.

American Cancer Society. Available at <https://www.cancer.org/content/dam/cancerorg/research/cancer-facts-and-statistics/annualcancer-facts-and-figures/2020/cancer-facts-andfigures-2020.pdf>. Accessed April 28, 2020.

Barlogie et al. In: *Williams Hematology*. 7th ed. 2006:1501.

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24. Erratum in: *Lancet*. 2021;398(10307):1216.

Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. *Blood*. 2016;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.

Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet*. 2010;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Erratum in: *Lancet*. 2011 Nov 26;378(9806):1846.

Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. *N Engl J Med*. 2022;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.

Chari A, Vogl DT, Gavriatopoulou M, et al. *N Engl J Med*. 2019;381(8):727-738. doi: 10.1056/NEJMoa1903455.

Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. *Front Immunol*. 2018;9:1821. doi: 10.3389/fimmu.2018.01821.

D'Agostino M, Boccadoro M, Smith EL. Novel immunotherapies for multiple myeloma. *Curr Hematol Malig Rep*. 2017;12(4):344-357. doi: 10.1007/s11899-017-0397-7.

Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med*. 2014;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. *J Immunol*. 1998;160(1):395-402.

Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. *Bone Marrow Transplant*. 2021;56(1):9-19. doi: 10.1038/s41409-020-01023-w. Epub 2020 Aug 7.

Dimopoulos MA, Delimpasi S, Simonova M, et al. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study. *J Clin Oncol*. 2020;38(15_suppl):8501-8501. doi: 10.1200/JCO.2020.38.15_suppl.850.

Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. *Hematol J*. 2003;4(6):379-98. Erratum in: *Hematol J*. 2004;5(3):285.

Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet*. 2017;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.

Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med*. 2019;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

Faiman B, McBride A, Devine H, et al. New agents in the treatment of multiple myeloma. *J Adv Pract Oncol*. 2016;7(suppl 1):45-52.

Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

Hoffman R. *Hematology: Basic Principles and Practice, 5th Ed*. Churchill Livingstone; 2008.

Holstein SA, Grant SJ, Wildes TM. Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: Moving into the future. *J Clin Oncol*. 2023;41(27):4416-4429. doi: 10.1200/JCO.23.00512. Epub 2023 Jul 20.

International Myeloma Foundation. 2007. Available at www.myeloma.org. Accessed Oct. 26, 2023.

Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells

expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol*. 2015;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. *Nat Rev Cancer*. 2002;2(3):175-87. doi: 10.1038/nrc746.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet*. 2015;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

Lee DW, Santomaso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol Blood Marrow Transplant*. 2019;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.

Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. *Nat Med*. 2023;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15.

Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol*. 2019;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

Mailankody S, Devlin SM, Landa J, et al. GPRC5D-targeted CAR T cells for myeloma. *N Engl J Med*. 2022;387(13):1196-1206. doi: 10.1056/NEJMoa2209900.

Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiol Rev*. 2008;88(3):841-86. doi: 10.1152/physrev.00035.2007.

Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med*. 2018;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 2014;371(16):1507-17. doi: 10.1056/NEJMoa1407222. Erratum in: *N Engl J Med*. 2016;374(10):998.

Mikhael J, Noonan KR, Faiman B, et al. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. *Clin Lymphoma Myeloma Leuk*. 2020;20(6):351-357. doi: 10.1016/j.clml.2019.12.026. Epub 2020 Mar 7.

Mikhael J. Treatment options for triple-class refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2020;20(1):1-7. doi: 10.1016/j.clml.2019.09.621. Epub 2019 Oct 9.

Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Erratum in: *Lancet*. 2019 Jun 14

Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384(8):705-716. doi: 10.1056/NEJMoa2024850.

National Cancer Institute. Available at Cancer.gov website. Accessed October 15, 2023.

National Cancer Institute. Available at <https://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed October 15, 2023.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Multiple Myeloma. Version 2.2024 4.2024— November 1, 2023 April 26, 2024.

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.

Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat Rev Clin Oncol*. 2018;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.

Neelapu SS, Tummala S, Kebriaei P, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. *Nat Rev Clin Oncol*. 2018;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13.

Neelapu SS. Managing the toxicities of CAR T-cell therapy. *Hematol Oncol*. 2019;37(Suppl 1):48-52. doi: 10.1002/hon.2595.

Paul B, Lipe B, Ocio EM, Usmani SZ. Induction therapy for newly diagnosed multiple myeloma. *Am Soc Clin Oncol Educ Book*. 2019;39:e176-e186. doi: 10.1200/EDBK_238527. Epub 2019 May 17.

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.

Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2018;93(8):981-1114. doi: 10.1002/ajh.25117.

Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2020;95(5):548-567. doi: 10.1002/ajh.25791. Erratum in: *Am J Hematol*. 2020;95(11):1444.

Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. *N Engl J Med*. 1998;338(22):1601-7. doi: 10.1056/NEJM199805283382207.

Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. *Br J Haematol*. 2012;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18.

Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. *Am Soc Clin Oncol Educ Book*. 2019;39:433-444. doi: 10.1200/EDBK_238691. Epub 2019 May 17.

Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. *Immunotherapy*. 2015;7(11):1187-99. doi: 10.2217/imt.15.77. Epub 2015 Sep 15.

Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. *Blood*. 2008;112(4):1329-37. doi: 10.1182/blood-2007-08-107292. Epub 2007 Sep 28.

Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Cancer Discov*. 2016;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.

Teclistamab (Tecvayli) [package insert]. Horsham PA: Janssen Biotech;2022. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf. Accessed Oct. 26, 2023.

Usmani SZ, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study. *J Clin Oncol*. 2023;41(suppl 16;abstr 8034). doi:10.1200/JCO.2023.41.16_suppl.80

Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. *Leukemia*. 2006;20(2):193-199. doi: 10.1038/sj.leu.2404067.

van de Donk N, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). *J Clin Oncol*. 2023;41:8011-8011(2023). doi:10.1200/JCO.2023.41.16_suppl.8011

Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. *Leukemia*. 2019;33(1):159-170.

Yi Lin, Thomas G. Martin, Saad Zafar Usmani, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. *J Clin Oncol*. 2023;41:(suppl 16; abstr 8009). doi: 10.1200/JCO.2023.41.16_suppl.8009.

Zhou X, Einsele H, Danhof S. Bispecific Antibodies: A new era of treatment for multiple myeloma. *J Clin Med*. 2020 ;9(7):2166. doi: 10.3390/jcm9072166.